Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management.
Lohit GargManasvi GuptaSyed Rafay Ali SabzwariSahil AgrawalManyoo AgarwalTalha NazirJeffrey GordonBabak BozorgniaMatthew W MartinezPublished in: Heart failure reviews (2020)
Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiomyopathy characterized by left ventricular hypertrophy and spectrum of clinical manifestation. Atrial fibrillation (AF) is a common sustained arrhythmia in HCM patients and is primarily related to left atrial dilatation and remodeling. There are several clinical, electrocardiographic (ECG), and echocardiographic (ECHO) features that have been associated with development of AF in HCM patients; strongest predictors are left atrial size, age, and heart failure class. AF can lead to progressive functional decline, worsening heart failure and increased risk for systemic thromboembolism. The management of AF in HCM patient focuses on symptom alleviation (managed with rate and/or rhythm control methods) and prevention of complications such as thromboembolism (prevented with anticoagulation). Finally, recent evidence suggests that early rhythm control strategy may result in more favorable short- and long-term outcomes.
Keyphrases
- hypertrophic cardiomyopathy
- atrial fibrillation
- left atrial
- left ventricular
- heart failure
- catheter ablation
- oral anticoagulants
- cardiac resynchronization therapy
- mitral valve
- direct oral anticoagulants
- left atrial appendage
- acute myocardial infarction
- ejection fraction
- end stage renal disease
- aortic stenosis
- newly diagnosed
- risk factors
- magnetic resonance
- percutaneous coronary intervention
- prognostic factors
- blood pressure
- peritoneal dialysis
- heart rate variability
- case report
- venous thromboembolism
- pulmonary hypertension
- chronic kidney disease
- acute heart failure